This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goffney, W. H. Articles by Storm, F. K. Search for Related Content PubMed PubMed Citation Articles by Goffney, W. H. Articles by Storm, F. K.

In Vitro and in Vivo Cytotoxicity of Rhodamine 123 Combined with Hyperthermia¹

Division of Surgical Oncology, John Wayne Cancer Clinic, Armand Hammer Laboratories, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California [W. H. G., J. H. W., D. H. K., D. C., D. N. K.]; Surgical Service, Veterans Administration Medical Center, Sepulveda, California [J. H. W., D. H. K.]; and Division of Surgical Oncology, University of Wisconsin School of Medicine, Madison, Wisconsin [F. K. S.]

Because both Rhodamine 123 (R123) and hyperthermia have been shown to be cytotoxic, we examined their effect, independently and in combination, on five different human malignant cell lines in vitro and on cultured melanoma cells grown intradermally in nude mice. The cell lines examined include two human melanomas, UCLA-SO-M14 and UCLA-SO-M21, the colon cancer cell line HT29, the human lung cancer cell line P3, and the human breast cancer cell line B231. R123 and hyperthermia, when used in combination, were found to be cytotoxic for these five different human malignant cell lines in vitro. The two agents together appear to enhance the cytotoxic effect of each alone, as documented by synergistic ratios ranging from 2.31 to 45 for the different cell lines. In the "nude" mouse model, animals were treated with a combination of R123 and hyperthermia (43°C for 90 min). A statistically significant (P = 0.04) decrease in tumor growth rate was observed when compared with the rate of tumor growth in untreated animals. The results suggest a potential role for R123 in combination with hyperthermia in the treatment of malignant cells.

¹ Supported by NIH Grant CA29605 and by the Veterans Administration Medical Research Service.

² Recipient of a Career Development Award from the American Cancer Society.

³ To whom requests for requests should be addressed, at Division of Surgical Oncology, University of Wisconsin School of Medicine, CSC G5/351, 600 Highland Avenue, Madison, WI 53792.

Received 12/12/88. Revised 7/ 6/89. Revised 10/16/89. Accepted 10/24/89.